Technologies

Summary

Vanderbilt researchers have created a novel technology for the diagnosis and monitoring of disease states using the rheological properties of a blood sample with a lateral flow membrane.

Addressed Need

Sickle Cell Disease (SCD) is expected to afflict over 14 million newborns by 2050 and there is an acute need for early diagnosis of the disease in low resource setting. Current diagnostics require highly trained personnel, are limited to laboratory settings , and fail to provide a viable alternative to the gold-standard HPLC analysis. There is a market opportunity for new technologies that provide clinically relevant assessments of sickling hemoglobin levels, such as the concentration of hemoglobin S, in a sample to aid in the diagnosis and management of SCD.